3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Breast Neoplasms
14
Polycystic Ovary Syndrome
12
Menorrhagia
7
Leiomyoma
7
Prostatic Neoplasms
2
Osteoporosis
2
Neoplasm Metastasis
2
Hyperandrogenism
2
Vaginitis
1
Triple Negative Breast Neoplasms
1
Sexual Dysfunction, Physiological
1
Neoplasms
1
Infertility, Female
1
Hot Flashes
1
Estrogen Receptor Positive Breast Cancer
1
Estrogen Levels Among Breast Cancer Patients
1
Coronary Disease
1
Cardiovascular Diseases
1
Breast Carcinoma In Situ
1
Atrophic Vaginitis
1
Anemia
1
Anatomic Stage III Breast Cancer AJCC v8
1
Abortion, Spontaneous
1
Interventions
Epoetin Alfa
53
Darbepoetin alfa
38
epoetin beta
12
ferric carboxymaltose
11
Lenalidomide
5
Cyclophosphamide
5
luspatercept
4
fludarabine phosphate
4
fludarabine
4
Erythropoietin
4
Cyclosporine
4
Cisplatin
4
Busulfan
4
Blood Transfusion
4
ACE-011
4
peginesatide
3
iron isomaltoside 1000
3
hematide
3
ferrous sulfate
3
ferric gluconate
3
Radiotherapy
3
Iron-Dextran Complex
3
Filgrastim
3
Ferric Oxide, Saccharated
3
Biopsy
3
Antilymphocyte Serum
3
thymoglobulin
2
telapristone acetate
2
ruxolitinib
2
ferrous fumarate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Anemia
×
Estradiol
×
Clear all
NCT00303784
2020-11-27
PATCH
University College, London
Phase 3
Unknown
2,200 enrolled